Bullous pemphigoid is a potentially debilitating autoimmune bullous disease presenting with urticarial plaques, subepidermal bullae, erosions, and pruritus, classically in elderly individuals. This ...

A Prescription Drug User Fee Act target date of June 20, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics ...

More patients treated with dupilumab experienced sustained disease remission and itch reduction at week 36 compared with those who received placebo. The Food and Drug Administration (FDA) has approved ...

Please provide your email address to receive an email when new articles are posted on . Steroid alternatives should be considered for patients with bullous pemphigoid, who are most likely to be ...

Please provide your email address to receive an email when new articles are posted on . Sustained disease remission occurred in 20% of the study cohort vs. 4% of the placebo group at week 36. 41% of ...

Dupilumab is now approved for bullous pemphigoid, showing efficacy in achieving sustained disease remission and reducing severity. The LIBERTY-BP ADEPT study demonstrated significant improvements in ...

The US Food and Drug Administration (FDA) has approved Sanofi and Regeneron’s Dupixent (dupilumab) as a treatment option for adults with bullous pemphigoid (BP), a condition that predominantly affects ...

Study met the primary and all key secondary endpoints in adults with moderate-to-severe disease; five times more patients achieved sustained disease remission with Dupixent than placebo Dupixent is ...

Anti-BP180 antibody levels demonstrated a moderate to strong correlation with the severity of bullous pemphigoid (BP), in a meta-analysis highlighting the potential of anti-BP180 as a tool to monitor ...

bullous pemphigoid leg The relationship between bullous pemphigoid and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Regardless of the diagnosis of type 2 diabetes, patients with bullous ...